Cell MedX Corp
Cell MedX Corp., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions in the United States. The company develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System fo… Read more
Cell MedX Corp (CMXC) - Total Liabilities
Latest total liabilities as of November 2024: $1.02 Million USD
Based on the latest financial reports, Cell MedX Corp (CMXC) has total liabilities worth $1.02 Million USD as of November 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cell MedX Corp - Total Liabilities Trend (2013–2024)
This chart illustrates how Cell MedX Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cell MedX Corp Competitors by Total Liabilities
The table below lists competitors of Cell MedX Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aspen Pharmacare Holdings Ltd
JSE:APN
|
South Africa | ZAC51.00 Billion |
|
Western Acquisition Ventures Corp
NASDAQ:WAVS
|
USA | $3.98 Million |
|
Topview Optronics Corporation
TWO:6556
|
Taiwan | NT$472.37 Million |
|
Foods & Inns Limited
NSE:FOODSIN
|
India | ₹8.86 Billion |
|
Union Materials Corp
KO:047400
|
Korea | ₩123.97 Billion |
|
HYUNDAI BIOLAND Co.Ltd
KQ:052260
|
Korea | ₩27.91 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Cell MedX Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 26.63 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cell MedX Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cell MedX Corp (2013–2024)
The table below shows the annual total liabilities of Cell MedX Corp from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-05-31 | $872.58K | -64.94% |
| 2023-05-31 | $2.49 Million | +21.38% |
| 2022-05-31 | $2.05 Million | +25.92% |
| 2021-05-31 | $1.63 Million | -3.05% |
| 2020-05-31 | $1.68 Million | -14.45% |
| 2019-05-31 | $1.96 Million | +75.48% |
| 2018-05-31 | $1.12 Million | -23.54% |
| 2017-05-31 | $1.46 Million | -12.99% |
| 2016-05-31 | $1.68 Million | +130.14% |
| 2015-05-31 | $730.63K | +3283.17% |
| 2014-05-31 | $21.60K | +68.10% |
| 2013-05-31 | $12.85K | -- |